TY - CHAP
T1 - Evaluation of Vaccines and Therapeutics Against Ebolaviruses in the Domestic Ferret
AU - Cross, Robert W.
N1 - Publisher Copyright:
© The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature 2025.
PY - 2025
Y1 - 2025
N2 - Filoviruses, including Ebola and Marburg viruses, have caused periodic outbreaks of severe hemorrhagic disease in humans and nonhuman primates (NHP), resulting in major public health emergencies primarily in endemic areas. Filovirus disease has also been exported to developed nations, where it has been equally disruptive. There are four ebolaviruses (Ebola virus, Sudan virus, Bundibugyo virus, and Taï Forest virus) and two marburgviruses [Marburg virus (MARV) and Ravn virus] known to cause disease in humans, yet vaccines and therapeutics have only been approved for Ebola virus. NHPs have long served as the “gold standard” for medical countermeasure (MCM) evaluation and will most likely be required for regulatory approval for use in humans. However, screening and refinement of MCM dosing regimens are more efficiently and ethically performed in lower-order species such as rodents. However, mouse, hamster, and guinea pig models of filovirus infection require virus adaptation to cause disease in these animal models. Nonadapted filovirus strains can be used in immune-compromised rodent systems (genetic knockouts or humanized mice), but the immune defect must be accounted for when interpreting MCM efficacy. Recently, several groups have described the use of the domestic ferret (Mustela putorius furo) as a model for several ebolaviruses using wild-type (nonadapted) virus, with disease largely reflecting what has been observed in humans and NHPs. Interestingly, no disease has been observed in ferrets challenged with MARV. Here, we describe the use of the domestic ferret for vaccine and therapeutic evaluation against ebolaviruses.
AB - Filoviruses, including Ebola and Marburg viruses, have caused periodic outbreaks of severe hemorrhagic disease in humans and nonhuman primates (NHP), resulting in major public health emergencies primarily in endemic areas. Filovirus disease has also been exported to developed nations, where it has been equally disruptive. There are four ebolaviruses (Ebola virus, Sudan virus, Bundibugyo virus, and Taï Forest virus) and two marburgviruses [Marburg virus (MARV) and Ravn virus] known to cause disease in humans, yet vaccines and therapeutics have only been approved for Ebola virus. NHPs have long served as the “gold standard” for medical countermeasure (MCM) evaluation and will most likely be required for regulatory approval for use in humans. However, screening and refinement of MCM dosing regimens are more efficiently and ethically performed in lower-order species such as rodents. However, mouse, hamster, and guinea pig models of filovirus infection require virus adaptation to cause disease in these animal models. Nonadapted filovirus strains can be used in immune-compromised rodent systems (genetic knockouts or humanized mice), but the immune defect must be accounted for when interpreting MCM efficacy. Recently, several groups have described the use of the domestic ferret (Mustela putorius furo) as a model for several ebolaviruses using wild-type (nonadapted) virus, with disease largely reflecting what has been observed in humans and NHPs. Interestingly, no disease has been observed in ferrets challenged with MARV. Here, we describe the use of the domestic ferret for vaccine and therapeutic evaluation against ebolaviruses.
KW - Ebola viruses
KW - Ferrets
KW - Marburg viruses
KW - Monoclonal antibodies
KW - Therapeutic
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85210440018&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85210440018&partnerID=8YFLogxK
U2 - 10.1007/978-1-0716-4256-6_19
DO - 10.1007/978-1-0716-4256-6_19
M3 - Chapter
C2 - 39585628
AN - SCOPUS:85210440018
T3 - Methods in Molecular Biology
SP - 281
EP - 295
BT - Methods in Molecular Biology
PB - Humana Press Inc.
ER -